Objective The study objective was to evaluate and update the safety data from randomized
controlled trials of tumor necrosis factor inhibitors in patients treated for rheumatoid arthritis …

Background To analyse available evidence on the efficacy and safety of anti-TNFα drugs
(infliximab, etanercept and adalimumab) for treating rheumatoid arthritis (RA). Methods We …

Objective: To evaluate the safety of biological treatments for rheumatoid arthritis (RA) using
results from randomised controlled trials (RCT). Methods: The literature was searched to …

Abstract Objective Randomized clinical trials (RCTs) evaluate the efficacy of treatments in
selected groups of patients defined by strict inclusion criteria. The value of these trials in …

Tumor necrosis factor-alpha (TNFα) plays a central role in rheumatoid arthritis (RA)
pathogenesis. There are cur-rently three available anti-TNFα agents for the treatment of RA …

Objective. This study aimed to investigate the efficacy, safety and survival of TNF-α inhibitors
in patients with RA. Methods. A total of 178 patients> 18 years of age were treated with TNF …

Background Optimal treatment for rheumatoid arthritis (RA) after inadequate response (IR) to
tumour necrosis factor α inhibitors (TNFi) remains uncertain. Objective To compare the …

The development of tumor necrosis factor (TNF) inhibitor therapy has revolutionized the
treatment of rheumatoid arthritis (RA). Unfortunately, no one single agent is fully effective in …

Objective. New treatments that inhibit the cytokines tumour necrosis factor α (TNFα) and
interleukin 1 (IL-1) in the treatment of rheumatoid arthritis have proven clinical effect against …

Objectives This study evaluated the comparative effectiveness of a tumour necrosis factor
inhibitor (TNFi) versus a non-TNFi (biological disease-modifying antirheumatic drugs …